Market Overview

UPDATE: Cowen and Company Downgrades Meridian Bioscience on Tough Road Ahead


In a report published Tuesday, Cowen and Company analyst Shaun Rodriguez downgraded Meridian Bioscience (NASDAQ: VIVO) from Outperform to Market Perform, but reiterated the $21.00 price target.

In the report, Cowen and Company noted, “Reaching 2013 revenue guidance would require a FH2 growth acceleration which we view as unlikely. Earnings guidance still appears achievable, but this is not likely enough of an offset. Accordingly, we see the bias to the downside and downgrade to Market Perform (from Outperform) with a $21 PT.”

Meridian Bioscience closed on Monday at $22.86.

Latest Ratings for VIVO

May 2019MaintainsSellSell
May 2019UpgradesUnderweightNeutral
Apr 2019DowngradesHoldSell

View More Analyst Ratings for VIVO
View the Latest Analyst Ratings

Posted-In: Cowen and Company Shaun RodriguezAnalyst Color Downgrades Analyst Ratings


Related Articles (VIVO)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Coca-Cola's Gary Fayard Blames Weak Q2 Results On Weather (KO)

UPDATE: Goldman Sachs Downgrades Standard Motor Products on Likely Earnings Growth Deceleration